Biblio Discovery — Demo Discovery Service

21 hasil untuk "Kenneth Cusi"

Menampilkan 1–20 · 1,24 detik · RSS

  1. Artikel Jurnal

    Esteatosis hepática metabólica: lo que el diabetólogo necesita saber

    Kenneth Cusi

    Revista de la Sociedad Argentina de Diabetes, Vol. 58 No. 3Sup · 2024 · Spanyol · DOAJ Scopus

    La esteatosis hepática metabólica (o MASLD, metabolic dysfunction-associated steatotic liver disease, anteriormente NAFLD) es una epidemia que afecta al ≥70% de los pacientes con diabetes mellitus tipo 2 (DM2) y que aumenta el riesgo de cirrosis y enfermedad cardiovascular. Existe la necesidad de…

  2. Artikel Jurnal

    From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options

    Amalia Gastaldelli; Kenneth Cusi

    JHEP Reports, Vol. 1 No. 4 · 2019 · Inggris · DOAJ Scopus

    Summary: The worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to have reached 25% or more in adults. NAFLD is prevalent in obese individuals, but may also affect non-obese insulin-resistant individuals. NAFLD is associated with a 2- to 3-fold increased risk of…

  3. Artikel Jurnal

    An endocrine perspective of nonalcoholic fatty liver disease (NAFLD)

    Romina Lomonaco; Janet Chen; Kenneth Cusi

    Therapeutic Advances in Endocrinology and Metabolism, Vol. 2 · 2011 · Inggris · DOAJ Scopus

    Endocrinologists are encountering patients with obesity-related complications such as metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) on a daily basis. Nonalcoholic fatty liver disease (NAFLD) is a liver condition characterized by insulin resistance, hepatic steatosis and frequently…

  4. Artikel Jurnal

    A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis

    Marina Kawaguchi-Suzuki; Kenneth Cusi; Fernando Bril dkk.

    Frontiers in Pharmacology, Vol. 9 · 2018 · Inggris · DOAJ Scopus

    Pioglitazone is used effectively to treat non-alcoholic steatohepatitis (NASH), but there is marked variability in response. This study examined whether genetic variation contributes to pioglitazone response variability in patients with NASH. This genetic substudy includes 55 participants of a…

  5. Artikel Jurnal Teks lengkap

    Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.

    Kristin Alexandra Dayton; Fernando Bril; Diana Barb dkk.

    PLoS ONE, Vol. 16 No. 6 · 2021 · Inggris · DOAJ Scopus

    BackgroundHypogonadism is reported to occur in non-alcoholic fatty liver disease (NAFLD), but earlier studies used low-sensitivity diagnostic techniques (CT, ultrasound), for NAFLD diagnosis. We hypothesized that if hypogonadism was due to NAFLD, and not solely attributable to underlying…

    Juga tersedia di: PLOS

  6. Artikel Jurnal

    Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants

    Fernando Bril; Srilaxmi Kalavalapalli; Romina Lomonaco dkk.

    JHEP Reports, Vol. 6 No. 7 · 2024 · Inggris · DOAJ Scopus

    Background & Aims: It has been postulated that carriers of PNPLA3 I148M (CG [Ile/Met] or GG [Met/Met]) develop metabolic dysfunction-associated steatotic liver disease (MASLD) in the absence of insulin resistance or metabolic syndrome. However, the relationship between insulin resistance and MASLD…

  7. Artikel Jurnal

    Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores

    Yonghui Wu; Xi Yang; Heather L Morris dkk.

    JMIR Medical Informatics, Vol. 10 No. 6 · 2022 · Inggris · DOAJ Scopus

    BackgroundNonalcoholic steatohepatitis (NASH), advanced fibrosis, and subsequent cirrhosis and hepatocellular carcinoma are becoming the most common etiology for liver failure and liver transplantation; however, they can only be diagnosed at these potentially reversible stages with a liver biopsy…

  8. Artikel Jurnal Teks lengkap

    Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis

    Johann Colomba; Silvia R. Netedu; Catherine Lehoux-Dubois dkk.

    PLOS ONE, Vol. 14 No. 7 · 2019 · Inggris · PLOS Scopus

    Aim: Cystic fibrosis (CF) patients are at high risk of developing CF-related diabetes (CFRD). In non-CF patients, liver disease, specifically steatosis and non-alcoholic fatty liver disease (NAFLD), is strongly associated with type 2 diabetes. We compared glycemic status and metabolic profiles in…

    Juga tersedia di: DOAJ

  9. Artikel Jurnal

    The Yin and Yang Between Plasma Glucose Levels and Cortisol Replacement Therapy in Schmidt’s Syndrome

    Christopher A. Newton MD; Eleni Sheehan MSN, ARNP; Kathleen Wyne MD, PhD dkk.

    Journal of Investigative Medicine High Impact Case Reports, Vol. 5 · 2017 · Inggris · DOAJ Scopus

    Objective: To illustrate how steroid replacement in adrenal insufficiency can influence the development of hypoglycemia in a patient with type 1 diabetes mellitus (T1D). Methods: We describe the case of a 36-year-old female patient with T1D and Addison’s disease (Schmidt’s syndrome) on multiple…

  10. Artikel Jurnal

    Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD

    Marc McLeod; Mario C. Chang; Anna Rushin dkk.

    Cell Reports Medicine, Vol. 5 No. 9 · 2024 · Inggris · DOAJ Scopus

    Summary: Metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence is increasing annually and affects over a third of US adults. MASLD can progress to metabolic dysfunction-associated steatohepatitis (MASH), characterized by severe hepatocyte injury, inflammation, and eventual…

  11. Artikel Jurnal

    Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study

    A. Sidney Barritt; Stephanie Watkins; Norman Gitlin dkk.

    Hepatology Communications, Vol. 5 No. 6 · 2021 · Inggris · DOAJ Scopus

    Much of the current data on nonalcoholic fatty liver disease (NAFLD) are derived from biopsy‐based studies that may introduce ascertainment and selection bias. Selection of patients for liver biopsy has implications for clinical practice and the reported epidemiology of NAFLD. The aim of this study…

  12. Artikel Jurnal

    Association of estimated liver fibrosis with carotid but not femoral atherosclerotic burden: the ILERVAS cohort

    Josep León-Mengíbar; María M. Malagón; Marcelino Bermúdez-López dkk.

    Frontiers in Endocrinology, Vol. 16 · 2026 · Inggris · DOAJ Scopus

    IntroductionAdvanced liver fibrosis, a key complication of metabolic dysfunction-associated steatotic liver disease, has been increasingly linked to extrahepatic conditions, including type 2 diabetes, obesity, and cardiovascular disease. However, the specific association of liver fibrosis in the…

  13. Artikel Jurnal

    Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study

    María Teresa Julián; Sílvia Ballesta; Guillem Pera dkk.

    Frontiers in Endocrinology, Vol. 13 · 2023 · Inggris · DOAJ Scopus

    ObjectiveTo investigate longitudinal changes in the liver stiffness measurement (LSM) in the general adult population without known liver disease and to describe its association with metabolic risk factors, with a special focus on subjects with non-alcoholic fatty liver disease (NAFLD) and…

  14. Artikel Jurnal

    Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease

    Juan Pablo Arab; Melisa Dirchwolf; Mário Reis Álvares-da-Silva dkk.

    Annals of Hepatology, Vol. 19 No. 6 · 2020 · Inggris · DOAJ Scopus

    Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20–30% of the general population. Furthermore, its prevalence is predicted to increase exponentially in the next decades, concomitantly with…

  15. Artikel Jurnal

    Advancing the global public health agenda for NAFLD: a consensus statement

    Jeffrey V. Lazarus; Henry E. Mark; Quentin M. Anstee dkk.

    Nature Reviews Gastroenterology & Hepatology · 2021 · Inggris · OpenAlex Scopus

    Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the…

  16. Artikel Jurnal

    A multisociety Delphi consensus statement on new fatty liver disease nomenclature

    Mary E. Rinella; Jeffrey V. Lazarus; Vlad Ratziu dkk.

    Annals of Hepatology, Vol. 29 No. 1 · 2024 · Inggris · DOAJ Scopus

    The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified…